OBJECTIVE: Osteoporosis is a skeletal disorder characterized by low bone mass and increased bone fragility associated with aging, menopause, smoking, obesity, or diabetes. Persistent inflammation has been identified as an instigating factor in progressive bone loss. In addition to the role of fibrin in coagulation, inordinate fibrin deposition within a tissue matrix results in increased local inflammation. Given that fibrin accumulation is a hallmark of osteoporosis-related comorbidities, we undertook this study to test the hypothesis that persistent fibrin deposition causes inflammatory osteoporosis. METHODS: Multiple imaging modalities, bone integrity metrics, and histologic analyses were employed to evaluate skeletal derangements in relation to fibrin deposition, circulating fibrinogen levels, and systemic markers of inflammation in mice that were plasminogen deficient and in plasminogen-deficient mice that were concomitantly either fibrinogen deficient or carrying a mutant form of fibrinogen lacking the αM β2 binding motif. RESULTS: Mice generated with a genetic deficit in the key fibrinolytic protease, plasmin, uniformly developed severe osteoporosis. Furthermore, the development of osteoporosis was fibrin(ogen) dependent, and the derangements in the bone remodeling unit were mechanistically tied to fibrin(ogen)-mediated activation of osteoclasts via activation of the leukocyte integrin receptor αM β2 on monocytes and secondary stimulation of osteoblasts by RANKL. Notably, the genetic elimination of fibrin(ogen) or the expression of a mutant form of fibrinogen retaining clotting function but lacking the αM β2 binding motif prevented the degenerative skeletal phenotypes, resulting in normal local and systemic cytokine levels. CONCLUSION: Taken together, these data reveal for the first time that fibrin promotes inflammation-driven systemic osteoporosis, which suggests a novel association between hemostasis, inflammation, and bone biology.
OBJECTIVE:Osteoporosis is a skeletal disorder characterized by low bone mass and increased bone fragility associated with aging, menopause, smoking, obesity, or diabetes. Persistent inflammation has been identified as an instigating factor in progressive bone loss. In addition to the role of fibrin in coagulation, inordinate fibrin deposition within a tissue matrix results in increased local inflammation. Given that fibrin accumulation is a hallmark of osteoporosis-related comorbidities, we undertook this study to test the hypothesis that persistent fibrin deposition causes inflammatory osteoporosis. METHODS: Multiple imaging modalities, bone integrity metrics, and histologic analyses were employed to evaluate skeletal derangements in relation to fibrin deposition, circulating fibrinogen levels, and systemic markers of inflammation in mice that were plasminogen deficient and in plasminogen-deficient mice that were concomitantly either fibrinogen deficient or carrying a mutant form of fibrinogen lacking the αM β2 binding motif. RESULTS:Mice generated with a genetic deficit in the key fibrinolytic protease, plasmin, uniformly developed severe osteoporosis. Furthermore, the development of osteoporosis was fibrin(ogen) dependent, and the derangements in the bone remodeling unit were mechanistically tied to fibrin(ogen)-mediated activation of osteoclasts via activation of the leukocyte integrin receptor αM β2 on monocytes and secondary stimulation of osteoblasts by RANKL. Notably, the genetic elimination of fibrin(ogen) or the expression of a mutant form of fibrinogen retaining clotting function but lacking the αM β2 binding motif prevented the degenerative skeletal phenotypes, resulting in normal local and systemic cytokine levels. CONCLUSION: Taken together, these data reveal for the first time that fibrin promotes inflammation-driven systemic osteoporosis, which suggests a novel association between hemostasis, inflammation, and bone biology.
Authors: Dimitrios Davalos; Jae Kyu Ryu; Mario Merlini; Kim M Baeten; Natacha Le Moan; Mark A Petersen; Thomas J Deerinck; Dimitri S Smirnoff; Catherine Bedard; Hiroyuki Hakozaki; Sara Gonias Murray; Jennie B Ling; Hans Lassmann; Jay L Degen; Mark H Ellisman; Katerina Akassoglou Journal: Nat Commun Date: 2012 Impact factor: 14.919
Authors: Robert A Campbell; Adriana Vieira-de-Abreu; Jesse W Rowley; Zechariah G Franks; Bhanu Kanth Manne; Matthew T Rondina; Larry W Kraiss; Jennifer J Majersik; Guy A Zimmerman; Andrew S Weyrich Journal: Arterioscler Thromb Vasc Biol Date: 2017-08-03 Impact factor: 8.311
Authors: Lakmali Munasinghage Silva; Andrew Gary Lum; Collin Tran; Molly W Shaw; Zhen Gao; Matthew J Flick; Niki M Moutsopoulos; Thomas H Bugge; Eric S Mullins Journal: Blood Date: 2019-05-17 Impact factor: 22.113
Authors: Maureen A Shaw; Zhen Gao; Kathryn E McElhinney; Sherry Thornton; Matthew J Flick; Adam Lane; Jay L Degen; Jae Kyu Ryu; Katerina Akassoglou; Eric S Mullins Journal: J Neurosci Date: 2017-03-08 Impact factor: 6.167
Authors: Richard A Jacobson; Kiedo Wienholts; Ashley J Williamson; Sara Gaines; Sanjiv Hyoju; Harry van Goor; Alexander Zaborin; Benjamin D Shogan; Olga Zaborina; John C Alverdy Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-10-11 Impact factor: 4.052
Authors: Masato Yuasa; Nicholas A Mignemi; Jeffry S Nyman; Craig L Duvall; Herbert S Schwartz; Atsushi Okawa; Toshitaka Yoshii; Gourab Bhattacharjee; Chenguang Zhao; Jesse E Bible; William T Obremskey; Matthew J Flick; Jay L Degen; Joey V Barnett; Justin M M Cates; Jonathan G Schoenecker Journal: J Clin Invest Date: 2015-07-27 Impact factor: 14.808
Authors: Joni M Prasad; Oscar Negrón; Xinli Du; Eric S Mullins; Joseph S Palumbo; Jessica M Gilbertie; Magnus Höök; Steven P Grover; Rafal Pawlinski; Nigel Mackman; Jay L Degen; Matthew J Flick Journal: Proc Natl Acad Sci U S A Date: 2020-12-21 Impact factor: 12.779